Treatment with tyrosine kinase inhibitors (TKIs) results in normal life expectancy for most patients with chronic myeloid leukemia, but patients with resistance to frontline treatment, including those with a T315I mutation, present a challenge. In this population, a major molecular response can often be achieved with either ponatinib, a US Food and Drug Administration–approved TKI, or the more recently approved asciminib, which is the first BCR:ABL1 inhibitor to specifically target the ABL myristoyl pocket (STAMP).
Despite good response to therapy, some patients may still report intolerance to side effects necessitating dose reductions. Others who have achieved sustained remission may be candidates for treatment discontinuation, providing certain criteria are met.
In this ReCAP, Dr Ehab Atallah, from the Medical College of Wisconsin, discusses strategies to navigate these situations on the basis of recent evidence.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Common Challenges in Treating Chronic Myeloid Leukemia - Medscape - Oct 20, 2022.
Comments